Financing ·
Inventiva S.A. filed an amendment to correct a material error in its July 29, 2026 press release regarding preliminary…
IVEVFInventiva S.A.
Inventiva S.A. filed an amendment to correct a material error in its July 29, 2026 press release regarding preliminary first-half financial results. The company mistakenly stated that potential proceeds for Tranche C of its Debt Financing Transaction were €20 million; the corrected figure is €55 million. As of June 30, 2026, Inventiva held €166.1 million in cash and equivalents plus €67.8 million in short-term deposits. Net cash used in operating activities was (€48.7) million, while net cash generated from financing activities was €50.9 million, reflecting a comprehensive capital structure optimization completed in June 2026 that included an equity offering of €103 million and debt transactions totaling €75 million. The company expects its current resources to fund operations through the end of Q2 2027, extending to Q1 2028 if Tranche C proceeds are realized and warrants are exercised. Inventiva is a clinical-stage biopharmaceutical company focused on developing lanifibranor for metabolic dysfunction-associated steatohepatitis.